<DOC>
	<DOC>NCT00242775</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.</brief_summary>
	<brief_title>Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Diagnosed with asthma since at least 6 months prior to first visit Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit At least one asthma exacerbation more than one but less than twelve months prior to first visit Respiratory infection affecting asthma within 30 days before first visit Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit Any significant disease or disorder that may jeopardize the safety of the patient Additional inclusion and exclusion criteria will be evaluated by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>